Trials / Completed
CompletedNCT02666105
Exemestane in Post-Menopausal Women With NSCLC
Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exemestane | One 25 mg tablet once daily for a minimum of 6 weeks |
Timeline
- Start date
- 2018-09-27
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2016-01-28
- Last updated
- 2023-05-31
- Results posted
- 2023-05-31
Locations
18 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02666105. Inclusion in this directory is not an endorsement.